US Stock MarketDetailed Quotes

SSKN Strata Skin Sciences

Watchlist
  • 3.080
  • -0.070-2.22%
Close Dec 2 16:00 ET
12.85MMarket Cap-1184P/E (TTM)
Full Hours
  • 5D
  • Daily
  • Weekly
  • Monthly
  • 1Q
  • 1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

Comments

    $Strata Skin Sciences (SSKN.US)$ STRATA Skin Sciences Announces Favorable Court Order in Complaint Against LaserOptek, Monarch Laser Services, and The Pinnacle Health Group
    1 MINUTE AGO, 8:15 AM EST
    VIA GLOBENEWSWIRE
    HORSHAM, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces t...
    $Strata Skin Sciences (SSKN.US)$
    STRATA Skin Sciences Announces Favorable Court Order in Complaint Against LaserOptek, Monarch Laser Services, and The Pinnacle Health Group
    STRATA Skin Sciences (NASDAQ: SSKN) announces a favorable court order in its complaint against LaserOptek, Monarch Laser Services, and The Pinnacle Health Group. The order, issued by the US District Court for Eastern Pennsylvania, enjoins LaserOptek and Pinnacle from marketing Pallas lasers with claims about CPT Codes 9692...
    $Strata Skin Sciences (SSKN.US)$
    STRATA Skin Sciences Announces Approval of XTRAC Momentum™ 1.0 Device in Japan
    STRATA Skin Sciences (NASDAQ: SSKN) has received approval for its XTRAC Momentum™ 1.0 device from Japan's Ministry of Health, Labor and Welfare. The device, initially launched in the U.S. in early 2022, will be commercially rolled out in Japan through JMEC Co., , STRATA's strategic partner and distributor. STRATA's excimer devices are currently used in over 300 Japanese hospitals an...
    $Strata Skin Sciences (SSKN.US)$
    STRATA Skin Sciences’ TheraClear®X Acne Therapy System Found Safe and Effective in Study Published in Peer Reviewed Journal
    $Strata Skin Sciences (SSKN.US)$
    STRATA Skin Sciences Pre-Announces Second Quarter 2024 Financial Results
    Positive
    Estimated Q2 2024 revenue between $8.0 million and $8.4 million.
    Growth in the domestic installed base of TheraClear®X devices from 104 to 117 units.
    Cash, cash equivalents, and restricted cash of $6.8 million.
    Strategic initiatives to drive device utilization and direct-to-consumer activities.
    Increased media coverage potentially enhancing market awareness.
    Negative
    Decli...
Read more

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data